Koliber Biosciences focuses on leveraging data science to enhance biological research and development across various sectors, particularly in biotechnology and healthcare. The company offers a comprehensive suite of services that includes traditional statistical analyses, data visualization, and advanced machine learning and artificial intelligence (AI) solutions. Their machine learning capabilities are designed to tackle the complexities of biological data, enabling the creation of predictive models that can pre-screen novel variants or conditions before laboratory testing. This approach not only identifies key performance drivers but also generates valuable insights applicable to drug discovery, diagnostics, and genome engineering.

In addition to their machine learning initiatives, Koliber Biosciences has developed an AI-assisted peptide drug discovery platform that analyzes complex datasets derived from peptide variants. This platform utilizes both classical peptide features and proprietary deep learning encodings to pinpoint performance-driving features and predict in vivo results from in vitro assays. Furthermore, the company is advancing genome engineering technologies for microbiome and probiotic strains, which aim to create novel microbiome therapeutics and enhance existing probiotic functions. These innovations are supported by funding from the National Science Foundation and the National Institutes of Health, underscoring Koliber's commitment to integrating cutting-edge technology into biological research.

United States

Koliber Biosciences is a computational biology company that specializes in building machine learning models for peptide discovery and optimization with a focus on enhancing peptide activity through innovative technology.

Koliber Biosciences

Company Details